Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged inAllNewsSportCultureLifestyleNovo Nordisk's global patent for popular weight-loss jabs Wegovy and Ozempic is set to expire in several countries from early 2026. This expiration will enable other pharmaceutical companies to produce significantly cheaper 'generic' versions of the semaglutide-based medications. Medicines UK, representing generic manufacturers, suggests prices could fall by 70-90 per cent, potentially making the jabs available for as little as £20 a month. While the patent expires in countries like India and Canada from 2026, it will not do so in the UK until 2031, raising concerns about unregulated imports. Novo Nordisk has dismissed Medicines UK's comments as speculative, stating no current plans to alter their UK offering. In fullNew drugmakers could soon offer ‘£20-a-month’ Ozempic-style weight-loss jabsThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in
Weight-loss jabs could soon get a lot cheaper. Here’s why
Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged inAllNewsSportCultureLifestyleNovo Nordisk's global patent for popular weight-loss jabs Wegovy and Ozempic is set to expire in several countries from early 2026. This expiration will enable other pharmaceutical companies to produce significantly cheaper 'generic' versions of the semaglutide-based medications. Medicines UK, representing generic manufacturers, suggests prices could fall by 70-90 per cent, potentially making the jabs available for as little as £20 a month. While the patent expires in countries like India and Canada from 2026, it will not do so in the UK until 2031, raising concerns about unregulated imports. Novo Nordisk has dismissed Medicines UK's comments as speculative, stating no current plans to alter their UK offering. In fullNew drugmakers could soon offer ‘£20-a-month’ Ozempic-style weight-loss jabsThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in
